Three Strikes, But Not Out Yet, Lilly’s Donanemab Approval Delayed Again

Accelerated Approval Snub Was More Than A Year Ago

 
• By Mandy Jackson
  
Brain Xray
Donanemab safety and efficacy both are likely topics for the Adcomm • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip